The PubMed entry describes the F-SHARP Phase I/II clinical trial examining dose-escalated focal salvage high-dose-rate brachytherapy for patients with radiorecurrent prostate cancer. The record names the work as a clinical trial published in Journal of Clinical Oncology (J Clin Oncol) in 2026 and supplies the DOI and PMID. The registry-style entry makes clear what the trial set out to test at a conceptual level: focal, intensified local therapy in the salvage setting coupled with molecular risk stratification.
This description is concise. It identifies the trial phase (Phase I/II) and the core interventions. The PubMed metadata itself, however, does not include the trial’s primary and secondary endpoints in the visible excerpt, nor does it provide dosing details or outcome data. Interested clinicians should consult the full-text JCO article for the definitive protocol and results.
The citation lists a multidisciplinary author group led by Abhishek A Solanki and includes clinical investigators from multiple academic centers and a commercial molecular diagnostics company. Affiliations in the PubMed record include departments of Radiation Oncology, Urology, Pathology and Laboratory Medicine, Cancer Biology, and Veracyte, Inc. Specific institutions named are Loyola University Medical Center, University of Texas Southwestern, University of Washington, University of Chicago, and University of Virginia.
The presence of Veracyte authors implies that the genomic classifier component used a commercial molecular assay or analytic platform; the entry attributes this to the study team but does not enumerate the classifier’s name, version, or analytic thresholds in the excerpt.
The trial title specifies a focal salvage strategy using high-dose-rate (HDR) brachytherapy with dose escalation. That signals investigators delivered concentrated, localized radiotherapy to recurrent intraprostatic disease rather than whole-gland retreatment. The Phase I/II designation further suggests the protocol assessed both safety/tolerability (Phase I) and preliminary efficacy or feasibility (Phase II).
The PubMed abstract snippet does not include regimen details such as fractionation, total prescribed dose, catheter placement techniques, planning margins, or organ-at-risk constraints. The excerpt also omits enrollment criteria, prior primary therapies received by participants, and time from initial treatment to recurrence. Those protocol elements are required to interpret toxicity and disease-control findings and are available only in the full article.
The trial incorporated a genomic classifier for risk stratification, as indicated by author affiliations with Veracyte and explicit mention in the title. The presence of molecular risk assessment implies the study evaluated whether genomic risk categories inform patient selection for focal salvage and/or correlate with outcomes after dose escalation.
The PubMed record does not provide the classifier’s analytic performance, the proportion of patients in each risk stratum, or any association between classifier results and clinical endpoints. The excerpt does not state whether classifier data altered treatment allocation or dose levels. Readers must reference the full text to determine how genomic risk influenced enrollment, treatment planning, or outcomes analysis.
The PubMed entry gives full citation metadata: J Clin Oncol. 2026 Nov 20;44(33):3213-3226. DOI 10.1200/JCO-25-02730; PMID 42874014. The page links to full-text access via the ASCO Journals Atypon platform. Authors, affiliations, and the clinical trial designation are clearly listed in the record. These indexing details enable retrieval of the primary manuscript for complete methods and results.
The record shows the study underwent peer-reviewed publication in a major oncology journal. That indicates formal editorial and review processes took place, but the PubMed excerpt does not reproduce peer-review comments, supplementary material, or trial registry identifiers within the visible content.
The PubMed excerpt supplies robust bibliographic metadata and a clear statement of the trial’s aims but stops short of reporting numerical results, toxicity profiles, efficacy outcomes, sample size, statistical analyses, or follow-up duration. The source did not include those specific trial data in the provided snippet. The Atypon/ASCO Journals link provided on the PubMed page directs readers to the full-text article, which is the only place to obtain complete protocol details, dosing regimens, endpoint definitions, and outcome statistics.
Limitations noted here reflect the content of the PubMed record used as the source. This summary deliberately avoids inferring outcomes or methods not printed in the excerpt. For clinical decision-making or guideline interpretation, consult the published JCO article and any linked supplementary files or clinical trial registry entries to review the trial’s full dataset and methodology.